Clinical trial
A Comparison of BMS-232632 With Efavirenz, Each in Combination With…
NCT00013897 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00013897 |
|---|---|
| Title | A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine |
| Official title | A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir, Lamivudine/Zidovudine, Efavirenz |
| Start date | Feb 1, 2001 |
| Primary completion | Apr 1, 2003 |
| Completion | Apr 1, 2003 |
| First posted | Aug 31, 2001 |
| Last update posted | May 4, 2011 |
| Countries | Austria, Belgium, Canada, Chile, Costa Rica, France, Germany, Guatemala, Hungary, Israel, Italy, Malaysia and 12 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: